Research / ANGI / Fundamental state Inspectable configuration
State dimensions Filing 0001705110-21-000015 General Corporate
Debt relative to revenue 25th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.debt_to_revenue
49.05% · OPTIONAL · VALID
Capex intensity 25th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.capex_revenue_ratio
3.58% · OPTIONAL · VALID
Operating cash generation 27th Own-history percentile · N=11
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
12.84% · OPTIONAL · VALID
Revenue growth 25th Own-history percentile · N=8
Evidence method Yoy · gp.fundamentals.revenue
10.69% · CORE · VALID
Operating margin 42th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.operating_margin
-0.43% · CORE · VALID
R&D intensity 42th Own-history percentile · N=12
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4.69% · OPTIONAL · VALID
SBC intensity 42th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
5.70% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 31 states Self-history eligible
Sep 30, 2021 7/7 normalized Level 3 Dec 31, 2021 6/6 normalized Level 3 Mar 31, 2022 6/6 normalized Level 3 Jun 30, 2022 6/7 normalized Level 3 Sep 30, 2022 6/7 normalized Level 3 Dec 31, 2022 6/7 normalized Level 3 Mar 31, 2023 6/7 normalized Level 3 Jun 30, 2023 6/7 normalized Level 3 Sep 30, 2023 6/7 normalized Level 3 Dec 31, 2023 5/6 normalized Level 3 Mar 31, 2024 5/6 normalized Level 3 Jun 30, 2024 6/6 normalized Level 3 Sep 30, 2024 6/6 normalized Level 3 Dec 31, 2024 6/6 normalized Level 3 Mar 31, 2025 7/7 normalized Level 3 Jun 30, 2025 7/7 normalized Level 3 Sep 30, 2025 7/7 normalized Level 3 Dec 31, 2025 6/6 normalized Level 3 Mar 31, 2026 7/7 normalized Level 3 Jun 30, 2026 7/7 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 187.01%
Current 49.05%
Delta -137.96% Capex Intensity Increased
Previous 3.33%
Current 3.58%
Delta 0.25% Cash Generation Increased
Previous 11.64%
Current 12.84%
Delta 1.20% Growth Increased
Previous 9.11%
Current 10.69%
Delta 1.58% Profitability Increased
Previous -0.77%
Current -0.43%
Delta 0.34% R And D Intensity Increased
Previous 4.51%
Current 4.69%
Delta 0.18% Sbc Intensity Increased
Previous 3.77%
Current 5.70%
Delta 1.93% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.